Osama Mahmoud Mehanna

Prof. Osama Mahmoud Mehanna

Physiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt, Cairo, Al Qāhirah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2020 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
PDF file
OAOsama Mohamed Abo‐Salem
Osama Mohamed Abo‐Salem
TATarek Mohamed Ali
Tarek Mohamed Ali
GHGamaleldin Ibrahim Harisa
Gamaleldin Ibrahim Harisa
Osama Mahmoud MehannaOsama Mahmoud Mehanna
Osama Mahmoud Mehanna
IYIbrahim Hamdy Younos
Ibrahim Hamdy Younos
WAWaleed Hassan Almalki
Waleed Hassan Almalki
1

22 December 2017 in Archives of Physiology and Biochemistry
Verified
Journal Article
Closed access
Osama Mahmoud MehannaOsama Mahmoud Mehanna
Osama Mahmoud Mehanna
AAAhmad El Askary
Ahmad El Askary
SASaad Al-Shehri
Saad Al-Shehri
BEBasem El-Esawy
Basem El-Esawy
The goal of this study was to investigate the effect of different phosphodiesterase inhibitors (PDEIs), on renal oxidant/antioxidant balance in diabetic rats. Our study was conducted on 125 rats, diabetes was induced in 100 rats by a single administration of streptozocin (STZ). Diabetic rats were divided into four equal groups. The first group was assigned as diabetic control, the remaining three groups were treated with pentoxifylline, sildenafil and milrinone via drinking water for 15 successive days, another group of 25 normal rats was assigned as non-diabetic control. Significant increase in plasma levels of glucose, urea, creatinine, malondialdehyde (MDA), and nitric oxide (NO) with a concomitant decrease in the levels of insulin, reduced glutathione (GSH), glutathione peroxidase (Gpx), superoxide dismutase (SOD), catalase (CAT), and total antioxidant capacity (TAC) were observed in diabetic rats. These alterations were reverted back to near normal level after treatment with PDEIs. Our data seem to suggest a potential role of PDEIs in maintaining health in diabetes by reducing the progression of diabetic nephropathy.
1

1 January 2021 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
Osama Mahmoud MehannaOsama Mahmoud Mehanna
Osama Mahmoud Mehanna
AAAhmad El Askary
Ahmad El Askary
EAEbtesam Ali
Ebtesam Ali
BEBasem El Esawy
Basem El Esawy
TFTamer FathAlla
Tamer FathAlla
AGAmal F Gharib
Amal F Gharib
Background: There is great variability in clinical presentation of COVID-19 worldwide. The current study evaluated the impact of obesity and its related complications on the course of COVID-19 in Egyptian patients. Methods: We included 230 COVID-19 Egyptian patients from Tanta City. According to their body-mass index (BMI), patient were divided into three groups: normal weight (BMI < 25 kg/m2), overweight (BMI > 25–< 30 kg/m2), and obese (BMI ≥ 30 kg/m2). Patients’ glycemic status, lipid profile, and serum levels of acute-phase reactants were assessed. The number of patients receiving intensive care and the number of deaths in each group were counted. Results: Mean values of random blood sugar, serum cholesterol, triglycerides, serum ferritin, erythrocyte-sedimentation rate, LDH, CRP, D-dimer levels, and blood pressure were significantly higher in obese patients (165.6, 129.5, 105, 1,873, 26, 403, 56.45, 977.16 and 142/87, respectively) than in normal-weight (97.2, 103.5, 70.4, 479, 17.4, 252, 23.2, 612.4, and 118.6/76.8, respectively) and overweight patients (111.4, 106.3, 78.13, 491.3, 19.8, 269.27, 25.42, 618.4, and 120.3/79.3, respectively). Lymphopenia was also significantly predominant in the obese group. Multivariate logistic regression analysis revealed that elevated serum triglycerides, total cholesterol, low density–lipoprotein cholesterol, blood pressure, ferritin, CRP, and low relative lymphocyte count were significant risk factors in obese COVID-19 patients. Conclusion: Obesity and its related complications increase the risk of presenting a more severe form of COVID-19 in Egyptian patients.
1

22 June 2023 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
NENoura Fathy Elmongy
Noura Fathy Elmongy
SMSamah Baleegh Meawad
Samah Baleegh Meawad
SEShimaa Zakaria Elshora
Shimaa Zakaria Elshora
AAAsmaa Huessiny Atwa
Asmaa Huessiny Atwa
AHAmal Mahmoud Hammad
Amal Mahmoud Hammad
WAWalaa Mohamed Ashry
Walaa Mohamed Ashry
1

1 August 2016 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
TATarek Ali
Tarek Ali
Osama Mahmoud MehannaOsama Mahmoud Mehanna
Osama Mahmoud Mehanna
AEAmgad Gaber Elsaid
Amgad Gaber Elsaid
AAAhmad El Askary
Ahmad El Askary
1

30 November 2023 in Pathophysiology
Verified
Journal Article
Open access
PDF file
MEMagdy Y. Elsaeed
Magdy Y. Elsaeed
Osama Mahmoud MehannaOsama Mahmoud Mehanna
Osama Mahmoud Mehanna
EAEzz-Eldin E. Abd-Allah
Ezz-Eldin E. Abd-Allah
MHMohamed Gaber Hassan
Mohamed Gaber Hassan
WAWalid Mostafa Ahmed
Walid Mostafa Ahmed
MMMohammed Hussein Mohammed
Mohammed Hussein Mohammed
Background: As the impacts of diabetes-induced reproductive damage are now evident in young people, we are now in urgent need to devise new ways to protect and enhance the reproductive health of diabetic people. The present study aimed to evaluate the protective effects of enalapril (an ACE inhibitor) and paricalcitol (a vitamin D analog), individually or in combination, on streptozotocin (STZ)-diabetes-induced testicular dysfunction in rats and to identify the possible mechanisms for this protection. Material and methods: This study was carried out on 50 male Sprague-Dawley rats; 10 normal rats were allocated as a non-diabetic control group. A total of 40 rats developed diabetes after receiving a single dose of STZ; then, the diabetic rats were divided into four groups of equivalent numbers assigned as diabetic control, enalapril-treated, paricalcitol-treated, and combined enalapril-and-paricalcitol-treated groups. The effects of mono and combined therapy with paricalcitol and enalapril on testicular functions, sperm activity, glycemic state oxidative stress, and inflammatory parameters, as well as histopathological examinations, were assessed in comparison with the normal and diabetic control rats. Results: As a result of diabetes induction, epididymal sperm count, sperm motility, serum levels of testosterone, follicle-stimulating hormone (FSH) as well as luteinizing hormone (LH), and the antioxidant enzyme activities, were significantly decreased, while abnormal sperm (%), insulin resistance, nitric oxide (NO), malondialdehyde (MDA), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were significantly increased, along with severe distortion of the testicular structure. Interestingly, treatment with paricalcitol and enalapril, either alone or in combination, significantly improved the sperm parameters, increased antioxidant enzyme activities in addition to serum levels of testosterone, FSH, and LH, reduced insulin resistance, IL-6, and TNF-α levels, and finally ameliorated the diabetes-induced testicular oxidative stress and histopathological damage, with somewhat superior effect for paricalcitol monotherapy and combined therapy with both drugs compared to monotherapy with enalapril alone. Conclusions: Monotherapy with paricalcitol and its combination therapy with enalapril has a somewhat superior effect in improving diabetes-induced testicular dysfunction (most probably as a result of their hypoglycemic, antioxidant, anti-inflammatory, and anti-apoptotic properties) compared with monotherapy with enalapril alone in male rats, recommending a synergistic impact of both drugs.
1